Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study

[1]  S. Miyano,et al.  Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. , 2020, Blood advances.

[2]  P. Gendron,et al.  Cryptic recurrent ACIN1‐NUTM1 fusions in non‐KMT2A‐rearranged infant acute lymphoblastic leukemia , 2020, Genes, chromosomes & cancer.

[3]  R. Stam,et al.  NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2 , 2019, Haematologica.

[4]  R. Pieters,et al.  Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Ashley D. Hill,et al.  PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia , 2019, Nature Genetics.

[6]  C. Pui,et al.  Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases , 2018, Proceedings of the National Academy of Sciences.

[7]  B. Schäfer,et al.  Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Valencia,et al.  Automatic identification of informative regions with epigenomic changes associated to hematopoiesis , 2016, bioRxiv.

[9]  Guido Marcucci,et al.  Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia , 2016, Nature Communications.

[10]  R. Pieters,et al.  Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Cheng Cheng,et al.  The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias , 2015, Nature Genetics.

[12]  R. Pieters,et al.  Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements , 2013, Leukemia.

[13]  H. Stunnenberg,et al.  BLUEPRINT: mapping human blood cell epigenomes , 2013, Haematologica.

[14]  Manolis Kellis,et al.  ChromHMM: automating chromatin-state discovery and characterization , 2012, Nature Methods.

[15]  H. Kimura,et al.  Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains , 2010, The EMBO journal.

[16]  R. Pieters,et al.  A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.